Premium
Ceftazidime versus Tobramycin/Ticarcillin in Treating Hospital Acquired Pneumonia and Bacteremia
Author(s) -
Rapp Robert P.,
Young Byron,
Foster Thomas S.,
Tibbs Phillip A.,
O'Neal Welton
Publication year - 1984
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1984.tb03360.x
Subject(s) - ceftazidime , tobramycin , ticarcillin , medicine , bacteremia , pneumonia , intensive care medicine , antibiotics , microbiology and biotechnology , pseudomonas aeruginosa , gentamicin , bacteria , biology , genetics
Thirty‐five patients in a neurosurgical intensive care unit who had nosocomial pneumonia and bacteremia were randomly assigned to receive either ceftazidime (Cef) or the combination of ticarcillin and pharmacokinetically adjusted doses of tobramycin (T/T). Fifteen of 17 patients (88%) who received Cef were cured or improved compared to 15 of 18 (83%) who received T/T. The original pathogen was eradicated from the respiratory secretion in 10 of 15 patients receiving Cef compared to only 6 of 18 patients receiving T/T (p = 0.12). All patients in both treatment groups who had positive blood cultures cleared the organism from the bloodstream. No cases of drug toxicity, including renal toxicity, were seen in either group. Cef used as a single agent in nosocomial pneumonias and bacteremias performed at least as well as T/T.